Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT04469127
Other study ID # 145358
Secondary ID
Status Not yet recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date September 30, 2024
Est. completion date August 30, 2025

Study information

Verified date April 2024
Source Advanced Imaging Projects, LLC
Contact Stanley Satz, Ph.D.
Phone 561-561 286-6842
Email ssatz@advancedimagingprojects.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is a Phase I/II clinical evaluation of a new investigational agent, Lutetium-177-DOTAGA-IAC (HurlutinTM Lu-177) to treat patients with unresectable angiogenic breast cancer who have previously been treated with at least one prior line of therapy.


Description:

This is a prospective, Phase I/II multi-center, interventional open-label study in a total of up to 100 subjects with angiogenic breast cancer. Phase I is to assess the safety and adequacy of a dose of HurlutinTM Lu-177 for up to three cycles, at 4-week intervals. It will include a dose expansion cohort of up to 20 patients. Phase II is to demonstrate the safety, dose adequacy, anti-tumor activity and efficacy of tumor targeted therapy using Lutetium-177-DOTAGA-IAC , as a second- or third-line treatment to extend survival and improve the quality of life of patients with angiogenic breast cancer.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 100
Est. completion date August 30, 2025
Est. primary completion date August 30, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years to 80 Years
Eligibility Inclusion Criteria: 1. Angiogenic breast tumor by immunohistochemistry confirmation. 2. Positive scan with PET/CT imaging with 18F-FET PET/CT. 3. Tumor progression resistant or refractory to at least one prior lines of standard chemotherapy which include trastuzumab and/or Ado-trastuzumab with or without chemotherapy agents. 4. At least 18 years of age 5. The patient is able and willing to provide informed consent and to comply with the requirements of this trial protocol. 6. ECOG score =3 7. Females of childbearing potential must have a negative serum pregnancy test or have had an intervention that renders pregnancy not possible 8. Adequate organ function, defined as: 1. Absolute neutrophil count (ANC) = 1.5 x 109/mL. 2. Hemoglobin (Hb) =10 g/dl (transfusion or use of EPO is permitted). 3. Platelets > 100,000/mm3 4. Creatinine = 1.5 x upper limit of normal (ULN) 5. AST or ALT = 2.5 x ULN (or =5 x ULN in case of liver metastasis) 6. Alkaline phosphatase =2.5 x ULN. Alkaline phosphatase may be more than 2.5 x ULN only in the case of bone metastases, and AST and ALT less than 1.5 x ULN. 7. Total bilirubin =1.5 mg/dl (higher bilirubin levels are permitted if the patient has Gilbert's syndrome). 9. Baseline LVEF =40% measured using echocardiogram or equilibrium isotopic ventriculography Exclusion Criteria: 1. Previously received external beam irradiation that includes more than 30% of bone marrow 2. Previously received external beam irradiation to a field that one kidney. 3. Previously received external beam irradiation to a field that includes the only known lesion. 4. Any uncontrolled significant medical, psychiatric or surgical condition or laboratory finding that would pose a risk to subject safety or interfere with study participation or interpretation of individual subject results. 5. Nephrectomy, renal transplant or concomitant nephrotoxic therapy putting the subject at high risk of renal toxicity during the study. 6. eGFR = 50. 7. Bone metastases are the only known lesions. 8. Patients with a body weight of 400 pounds or more or not able to enter the bore of the PET/CT scanner due to BMI, because of the compromise in image quality with CT, PET/CT and MRI that will result. 9. Inability to lie still for the entire imaging time (e.g., cough, severe arthritis, etc.). 10. Use of any other investigational therapeutic product within 30 days prior to dosing or known requirement for any other investigational agent prior to completion of all scheduled study assessments. 11. Recognized concurrent active infection. 12. Received any live (attenuated) vaccines within 30 days prior to Visit. 13. Recent or chronic treatment with medium-to-high-dose intravenous corticosteroids (methylprednisolone 60 mg/day or hydrocortisone 300 mg/day) within 8 weeks prior to Visit or oral corticosteroids of more than 20 mg prednisone (or equivalent) within 30 days prior to Visit 14. Any unresolved NCI-CTCAE Grade 2 or higher (except alopecia) from previous anti-tumour treatment and/or medical/surgical procedures/interventions. 15. Additional inclusion criterion for measure human dosimetry 1. Unable to comply with the requirements of the dosimetry imaging protocol 2. Due to potential radiation safety issues, patients with urinary drainage or diversion (e.g., in-dwelling Foley™ catheter, ureteroileostomy, etc.) will not be enrolled.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Lutetium-177-DOTAGA-IAC
Study participants be administered therapeutic doses of Lutetium-177-DOTAGA-IAC up to three treatments spaced 4 weeks apart.

Locations

Country Name City State
India Postgraduate Institute of Medical and Research Chandigarh
South Africa CM Johannesburg Academic Hospital, University of the Witwatersrand Johannesburg

Sponsors (3)

Lead Sponsor Collaborator
Advanced Imaging Projects, LLC Postgraduate Institute of Medical and Research, University of Witwatersrand, South Africa

Countries where clinical trial is conducted

India,  South Africa, 

References & Publications (2)

Baum RP, Kulkarni HR, Muller D, Satz S, Danthi N, Kim YS, Brechbiel MW. First-In-Human Study Demonstrating Tumor-Angiogenesis by PET/CT Imaging with (68)Ga-NODAGA-THERANOST, a High-Affinity Peptidomimetic for alphavbeta3 Integrin Receptor Targeting. Cance — View Citation

Kim YS, Nwe K, Milenic DE, Brechbiel MW, Satz S, Baidoo KE. Synthesis and characterization of alphavbeta(3)-targeting peptidomimetic chelate conjugates for PET and SPECT imaging. Bioorg Med Chem Lett. 2012 Sep 1;22(17):5517-22. doi: 10.1016/j.bmcl.2012.07 — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Specific Aim 1 To determine the safety and tolerability of fractionated administrations of 3 cycles of Lu-177-DOTAGA-IAC administered with 4 weeks between cycles in patients with high-risk Angiogenic Breast Cancer who have progressed on, or do not tolerate, best standard-of-care treatment.
Measurements used to assess the safety, tolerability and side-effects profile will include adverse events of any grade, grade 3 and 4 adverse events, withdrawals due to adverse events and dose reductions due to adverse events. National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE v.5.0) will be used to evaluate AE grade.
6 months
Primary Specific Aim 2 To determine the pharmacokinetics (PK) of Lu-177-DOTAGA-IAC. The area under the Time vs. Concentration curve for Lu-177-DOTAGA-IAC from injection to 72 h 6 months
Primary Specific Aim 3 To determine the whole-body biodistribution of Lu-177-DOTAGA-IAC. Percent injected dose per gram of tissue (%ID)/gm of Lu-177-DOTAGA-IAC. 6 months
Primary Specific Aim 4 To determine the radiation dosimetry of Lu-177-DOTAGA-IAC.Time points will be 0 and 120, 30 and 150, 60 and 180, or 90 and 210 min after injection.Time integrals of activity will be entered into the (Organ Level INternal Dose Assessment/ EXponential Modeling) OLINDA/EXM software. 6 months
Primary Specific Aims 5 To determine optimum cumulative fractionated administered dose. Increase dose range if a DLT (Dose Limiting Toxicity) develops or they do not have a T/B ratio >1. 6 months
Secondary Specific Aim 1 To determine the Objective Response Rate (ORR) of fractionated administration of Lu-177-DOTAGA-IAC.Percentage of subjects still alive. Percentage of subjects who achieved a best overall response of Complete Response [CR] or Partial Response [PR] according to RECIST 5.0 Criteria. 6-12 Months
See also
  Status Clinical Trial Phase
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Terminated NCT04123704 - Sitravatinib in Metastatic Breast Cancer Phase 2
Recruiting NCT05377047 - Stereotactic Ablative Radiotherapy for OligoMetastatic Breast Cancer N/A
Completed NCT03304210 - PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer Phase 1
Completed NCT05054374 - A Study of Mirdametinib on Its Own or in Combination With Fulvestrant in People With Solid Tumor Cancer Phase 1/Phase 2
Recruiting NCT05559528 - BRaziLian outcomE for metAStatic breasT Cancer
Active, not recruiting NCT05090358 - Preventing High Blood Sugar in People Being Treated for Metastatic Breast Cancer Phase 2
Recruiting NCT05033925 - Ficus Septica Leaves Fraction as a Complementary Therapy for Stadium IV Breast Cancer Patients Phase 1/Phase 2
Recruiting NCT03401359 - The Resistance and Immune Response to Palbociclib in Breast Cancer N/A
Active, not recruiting NCT03870919 - Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients N/A
Not yet recruiting NCT05860907 - Clinical Study of Huaier Granules in Patients With Advanced Breast Cancer Without Visceral Metastasis Phase 4
Completed NCT00393341 - Quantitation of Endothelial Progenitor Cells as Markers of Tumor Angiogenesis in Breast Cancer N/A
Recruiting NCT05625087 - Detection of Tumor DNA in the Blood of Patients Receiving Standard Therapy for Hormone Receptor-positive (HR+) Non-HER2 Expressing (HER2-) Metastatic Breast Cancer as a Tool to Select Those Who May Benefit From the Next Course of Fulvestrant in Combination With Alpelisib or Ribociclib Phase 2
Completed NCT04566458 - RWD Study in HER2+ mBC Patients in Third-Line Therapy
Recruiting NCT06075810 - A Study of Oral MBQ-167 in Participants With Advanced Breast Cancer Phase 1
Recruiting NCT04697043 - The Benefit of Surgery in Stage IV of Breast Cancer N/A
Recruiting NCT05837533 - Multicenter Study to Evaluate a Systematized Communication Model for Breast Cancer Patients N/A
Active, not recruiting NCT03324425 - Simvastatin Plus Dual Anti-HER2 Therapy for Metastatic Breast Cancer Phase 2
Recruiting NCT05670054 - Cyclin Dependant Kinase 4/6 (CDK4/6) Inhibitors as a Second Line Treatment in Metastatic Breast Cancer Patients Phase 3
Terminated NCT03202446 - Randomized Clinical Trial Evaluating the Use of the Laser-Assisted Immunotherapy (LIT/inCVAX) in Advanced Breast Cancer Phase 3